Loading...
•
Sep 30, 2023
Corvus Pharmaceuticals Q3 2023 Earnings Report
Corvus Pharmaceuticals reported financial results for the third quarter ended September 30, 2023.
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $6.0 million for the third quarter ended September 30, 2023, compared to a net loss of $14.8 million for the same period in 2022. As of September 30, 2023, Corvus had cash, cash equivalents and marketable securities of $32.2 million.
Phase 3 registrational clinical trial protocol finalized for soquelitinib (CPI-818) in peripheral T cell lymphoma (PTCL).
Multiple sites are preparing to initiate trial enrollment.
New data from soquelitinib Phase 1 T cell lymphoma trial accepted for presentation at the 65th ASH Annual Meeting and Exposition.
New publications highlight therapeutic potential of ITK inhibition in solid tumors and multiple autoimmune and allergic conditions.
Forward Guidance
Corvus expects full year 2023 net cash used in operating activities to be between approximately $22 million and $23 million, resulting in a projected cash balance of between $27 million and $28 million as of December 31, 2023. Based on its current plans, Corvus expects its cash to fund operations into late 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...